Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01618669 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
A Phase 3 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,147
- Enrollment target
NCT01618669 is a Phase 3 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,147 participants.
The verdict
NCT01618669, a Phase 3 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,147 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.
Interventions
- DRUG Regadenoson
- PROCEDURE Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,147 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01618669
The ClinicalTrials.gov registry entry for NCT01618669 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regadenoson is the first listed.
NCT01618669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01618669 about?
NCT01618669 is a clinical study titled "A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)". The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between tw...
What is the current status of trial NCT01618669?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,147 participants. The study started on 2012-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01618669?
The interventions under investigation include: Regadenoson (DRUG), Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) (PROCEDURE).
Who is sponsoring clinical trial NCT01618669?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.